For more than 40 years, in vitro fertilization (IVF) has revolutionized reproductive medicine, offering countless families the opportunity to conceive children who might otherwise not be born. Globally, assisted reproductive technologies, including IVF, have contributed to the birth of over 10 million individuals. Integral to these cutting-edge techniques is the option to evaluate embryos genetically before implantation, a practice aimed originally at detecting severe inherited disorders caused by mutations in single genes.
Preimplantation genetic testing (PGT) was first developed to screen embryos for monogenic diseases such as cystic fibrosis or hemophilia, conditions arising from specific, identifiable mutations. This type of genetic screening enables clinicians and prospective parents to significantly reduce the risk of passing along these debilitating disorders. However, recent technological progress has expanded the capabilities of genetic testing dramatically, enabling the assessment of complex traits governed by multiple genes rather than a single mutation.
A spotlight study published in Frontiers in Reproductive Health by Professor Tetsuya Ishii from Hokkaido University examines the advent of polygenic testing in embryos. Unlike traditional PGT which targets single-gene disorders, polygenic embryo testing seeks to predict susceptibility to intricate traits and late-onset diseases, including intelligence, diabetes, heart disease, and Alzheimer’s. While promising, this new frontier raises urgent questions about regulatory oversight, ethical considerations, and the reliability of genetic predictions when environmental factors remain unaccounted for.
Complex human traits and health conditions such as cognitive ability, physical appearance, schizophrenia, and cancer result from the interplay of numerous genetic variants combined with lifestyle and environmental influences. Scientific advances have led to the development of polygenic risk scores — statistical tools amalgamating the effects of many genetic variants to estimate an individual’s predisposition to particular traits or diseases. These scores form the basis for polygenic embryo screening (PGT-PS), representing a significant leap beyond monogenic-focused PGT.
Nonetheless, predicting outcomes for polygenic traits is fraught with uncertainty. Polygenic scores base their predictions solely on genetic data derived from large population studies while omitting critical environmental interactions and individual life experiences that shape phenotypic expression. Professor Ishii emphasizes that, despite their sophisticated algorithms, polygenic scores cannot guarantee outcomes because they do not capture the multifactorial nature of human development.
Regulation of polygenic embryo screening varies widely around the world, reflecting diverse cultural attitudes and ethical frameworks. Since 2019, fertility clinics in the United States have commercially offered polygenic embryo testing to prospective parents seeking to influence their child’s potential disease risks or characteristics. Surveys indicate a considerable portion of the American public supports using this technology to reduce disease risk, with some even open to non-medical trait selection.
Conversely, stringent limitations exist in many European nations. Germany and Italy permit embryo testing only for the exclusion of serious genetic diseases, explicitly prohibiting polygenic selection based on broader traits or predispositions. The United Kingdom currently bans the use of polygenic scores for embryo selection altogether. Many other countries operate without clear policies, which risks the unregulated expansion of such controversial technology amidst ongoing scientific debate about its clinical utility.
Beyond regulatory ambiguity lie profound ethical challenges. One key concern is that prospective parents might develop unrealistic expectations or place undue pressure on children based on uncertain genetic forecasts. Environmental factors, parental influence, and a child’s evolving individuality profoundly affect trait development, meaning polygenic scores do not provide deterministic predictions. This gap between expectation and reality invites complicated psychosocial consequences for families.
Furthermore, societal implications warrant careful reflection. The application of polygenic embryo screening touches on fears of returning to eugenics-like ideologies, where human worth and diversity could be jeopardized by attempts to “design” offspring to meet particular standards. It risks stigmatization of certain traits, reducing children to commodities tailored to satisfy parental preferences — a slippery slope with deep ethical ramifications for equity, diversity, and autonomy.
Another critical tension exists between expert caution and public attitudes. Geneticists and healthcare professionals often express skepticism about the current clinical validity of polygenic predictions for embryos, arguing that the science is not yet mature enough for widespread application. However, surveys reveal that some prospective parents are more enthusiastic about incorporating polygenic information into reproductive decisions, underlining a need for improved communication and education to bridge this divide.
Given the rapid evolution of reproductive genomic technologies, Ishii advocates for precautionary but balanced regulatory frameworks. Policymakers must establish clear guidelines that safeguard against premature or unethical applications of polygenic testing while fostering public literacy on the attainable and limited insights offered by genetic predictions. Transparent regulation will be essential in managing this technology’s societal integration responsibly.
In conclusion, polygenic embryo screening represents a promising yet complex frontier in reproductive medicine, bringing nuanced possibilities for disease risk reduction alongside troubling ethical and social questions. As science advances, a collaborative dialogue among clinicians, scientists, ethicists, and the public will be paramount to harnessing its potential benefits while mitigating harms. This measured approach will shape the future landscape of embryo selection in profound ways.
Subject of Research: People
Article Title: Precautions for polygenic embryo selection: prohibition or cautious use
News Publication Date: 26-Feb-2026
Web References:
International Committee for Monitoring Assisted Reproductive Technologies
DOI: 10.3389/frph.2026.1771127
Image Credits: Credit: Dr. Yasuyuki Mio, MIO Fertility Clinic
Keywords: Health and medicine, Ethics, Medical ethics, Human health, Human reproduction
